Brandon Mahal

Has grant

University of Miami Hospital
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

ASTRO-PCF Award to End Prostate Cancer

Open Date:

Close Date:

Grant: Close

CDMRP Prostate Cancer Research Program (PCRP) Health Disparity Fellowship Award

Open Date:

Close Date:

Articles (4)

Purpose: Alterations in BRAF have been reported in 3% to 5% of prostate cancer, although further characterization is lacking. Here, we describe the nature of BRAF alterations in prostate cancer using a large cohort from commercially available tissue and liquid biopsies subjected to comprehensive genomic profiling (CGP). Experimental Design: Tissue and liquid biopsies from patients with prostate cancer were profiled using FoundationOne CDx and FoundationOne Liquid CDx CGP assays, respectively. Tissue biopsies from non–prostate cancer types were used for comparison ( n = 275,151). Genetic ancestry was predicted using a single-nucleotide polymorphism (SNP) based approach. Results: Among 15,864 tissue biopsies, BRAF -activating alterations were detected in 520 cases (3.3%). The majority (463 samples, 2.9%) harbored class II alterations, including BRAF rearrangements (243 samples, 1.5%), K601E (101 samples, 0.6%), and G469A (58 samples, 0.4%). BRAF -altered prostate cancers were enriched for CDK12 mutations (OR, 1.87; 9.2% vs. 5.2%; P = 0.018), but depleted in TMPRSS2 fusions (OR, 0.25; 11% vs. 32%; P PTEN alterations (OR, 0.47; 17% vs. 31%; P APC alterations (OR, 0.48; 4.4% vs. 8.9%; P = 0.018) relative to BRAF wild-type (WT) disease. Compared with patients of European ancestry, BRAF alterations were more common in tumors from patients of African ancestry (5.1% vs. 2.9%, P P Conclusions: Activating BRAF alterations were detected in approximately 3% of prostate cancers, and most were class II mutations and rearrangements; BRAF V600 mutations were exceedingly rare. These findings suggest that BRAF activation in prostate cancer is unique from other cancers and supports further clinical investigation of therapeutics targeting the mitogen-activated protein kinase (MAPK) pathway.

Year:

2025

Background Despite palliative‐intent interventions’ ability to improve the quality of life of patients, significant inequalities persist in uptake. Such disparities are characterized by racial, socioeconomic, and geographic factors. However, less is known among disaggregated Hispanic populations. This study examines disparities in the receipt of palliative‐intent interventions among Hispanic subgroups with advanced lung, breast, and prostate cancer. Methods Via the National Cancer Data Base, data were collected on the receipt of palliative‐intent interventions among Hispanic subgroups diagnosed with American Joint Committee on Cancer analytic stage IV breast, lung, and prostate cancer between 2004 and 2021. Multivariate logistic regressions were conducted to quantify differences in the uptake of palliative‐intent care among Hispanic subgroups. Results Among 945,894 total patients, disaggregated analyses revealed reduced receipt of palliative‐intent interventions for patients with lung, breast, and prostate cancer of Mexican descent (lung, p < .001; breast, p < .001; prostate, p = .03) compared to non‐Hispanic White patients. Receipt for patients of South or Central American descent was reduced in comparison to non‐Hispanic White patients for lung and breast cancer (lung, p < .001; breast, p < .001). Uptake of palliative interventions for metastatic lung and breast cancer was reduced for patients of Cuban descent (lung, p < .001; breast, p = .03), and was lower for patients of Dominican descent with breast cancer, compared to non‐Hispanic White patients ( p = .05). Conclusions These findings demonstrate disparities in the receipt of palliative‐intent interventions among disaggregated Hispanic subgroups. This study highlights the need for disaggregated research to further characterize these disparities and their drivers. Community‐level and patient‐centric efforts may help to address these inequities.

Year:

2025

Purpose:Alterations in BRAF have been reported in 3-5% of prostate cancer, although further characterization is lacking. Here, we describe the nature of BRAF alterations in prostate cancer using a large cohort from commercially available tissue and liquid biopsies subjected to comprehensive genomic profiling (CGP). Experimental Design:Tissue and liquid biopsies from patients with prostate cancer were profiled using FoundationOne®CDx and FoundationOne®Liquid CDx CGP assays, respectively. Tissue biopsies from non-prostate cancer types were used for comparison (n=275,151). Genetic ancestry was predicted using a single nucleotide polymorphism-based approach. Results:Among 15,864 tissue biopsies, BRAF-activating alterations were detected in 520 cases (3.3%). The majority (463 samples, 2.9%) harbored Class II alterations, including BRAF rearrangements (243 samples, 1.5%), K601E (101 samples, 0.6%), and G469A (58 samples, 0.4%). BRAF-altered prostate cancers were enriched for CDK12 mutations (OR 1.87, 9.2% vs 5.2%, p=0.018), but depleted in TMPRSS2 fusions (OR 0.25, 11% vs 32%, p

Year:

2024

PURPOSE Indolent prostate cancer (PCa) is prevalent in the intended use population (adults age 50-79 years) for blood-based multicancer early detection (MCED) tests. We examined the detectability of PCa by a clinically validated, targeted methylation–based MCED test. METHODS Detectability by Gleason grade group (GG), clinical stage, association of detection status with tumor methylated fraction (TMeF), and overall survival (OS) were assessed in substudy 3 of Circulating Cell-Free Genome Atlas (CCGA; ClinicalTrials.gov identifier: NCT02889978 ) and PATHFINDER (ClinicalTrials.gov identifier: NCT04241796 ) studies. RESULTS Test sensitivity for PCa in substudy 3 of CCGA was 11.2% (47/420). The test detected 0 (0%) of 58 low-grade (GG1), 3 (1.9%) of 157 favorable intermediate-grade (GG2), 4 (5.1%) of 78 unfavorable intermediate-grade (GG3), and 36 (31.9%) of 113 high-grade (GG4 and 5) cancers and 3 (3.2%) of 95 stage I, 11 (4.7%) of 235 stage II, 7 (14.9%) of 47 stage III, and 22 (81.5%) of 27 stage IV cases. The median TMeF was higher for detected than nondetected cases (2,106.0 parts per million [PPM]; IQR, 349.8-24,376.3 v 24.4 PPM; IQR, 17.8-38.5; P < .05). Nondetected cases had better OS ( P < .05; hazard ratio [HR], 0.263 [95% CI, 0.104 to 0.533]) and detected cases had similar survival ( P = .2; HR, 0.672 [95% CI, 0.323 to 1.21]) compared with SEER adjusted for age, GG, and stage. Performance was similar in PATHFINDER, with no detected GG1/2 (0/13) or stage I/II (0/16) cases. CONCLUSION This MCED test preferentially detects high-grade, clinically significant PCa. Use in population-based screening programs in addition to standard-of-care screening is unlikely to exacerbate overdiagnosis of indolent PCa.

Year:

2024

Collaborators (6)

Alexander W. Wyatt

Assistant Professor

The University of British Columbia

CANADA
View details

Justin Hwang

Associate Professor

University of Minnesota

UNITED STATES
View details

Emmanuel S. Antonarakis

-

UNITED STATES
View details

Edward Christopher Dee

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Neeraj Agarwal

Faculty Member

Dana-Farber Cancer Institute

UNITED STATES
View details

Tanya Dorff

Associate Professor

City Of Hope National Medical Center

UNITED STATES
View details